Protagenic Therapeutics Inc New's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Protagenic Therapeutics Inc New (PTIX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Protagenic Therapeutics Inc New vs Its Competitors
- Scale: Protagenic Therapeutics Inc New ranks #461 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Protagenic Therapeutics Inc New's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Protagenic Therapeutics Inc new | - | - | - | Yes |
| Competitors combined (80) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PTIX Stock Performance relative to its Competitors
PTIX Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Climb Bio Inc | 282.9% | Outperformed |
| 3 | Gossamer Bio Inc | 282.9% | Outperformed |
| 4 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 5 | Dianthus Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Protagenic Therapeutics Inc New's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Protagenic Therapeutics Inc New's Comment on Competition and Industry Peers
Publicly Traded Peers of Protagenic Therapeutics Inc new
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Protagenic Therapeutics Inc new |
0.98 | - |
 Eli Lilly And Company |
1,209,663.60 | 86,462.00 |
 Johnson and Johnson |
676,352.29 | 99,335.00 |
 Abbvie Inc |
516,201.32 | 66,014.00 |
 Merck and Co Inc |
362,398.40 | 66,569.00 |
 Novartis Ag |
317,785.25 | 56,674.00 |
| SUBTOTAL | 4,038,616.81 | 636,327.20 |
Sign in to see all competitors of Protagenic Therapeutics Inc new.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Protagenic Therapeutics Inc new versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Protagenic Therapeutics Inc New's Competitors Named by the Company
Competitive relationships identified from Protagenic Therapeutics Inc New reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Sage Therapeutics Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Protagenic Therapeutics Inc New's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Protagenic Therapeutics Inc New's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Protagenic Therapeutics Inc new.
Protagenic Therapeutics Inc New's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Protagenic Therapeutics Inc new | 1 | - | 910,314 |
| Eli Lilly And Company | 1,209,664 | 1,729,240 | 551,594 |
| Johnson and Johnson | 676,352 | 705,504 | 114,311 |
| Abbvie Inc | 516,201 | 1,158,140 | 181,509 |
| Merck and Co Inc | 362,398 | 887,587 | 42,267 |
| Novartis Ag | 317,785 | 752,973 | 185,566 |
| PEERS TOTAL | 4,038,616 | 966,681 | 155,497 |
Sign in to see all peers for Protagenic Therapeutics Inc new.
Protagenic Therapeutics Inc New's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Abbott Laboratories | Non-US 57.70 % |
| Pfizer Inc | United States 63.93 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Protagenic Therapeutics Inc new.
Protagenic Therapeutics Inc New's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Protagenic Therapeutics Inc New's industry classification, broader than the peer set above. Market cap in millions of $.Protagenic Therapeutics Inc New ranks #461 of 495 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 461 | Protagenic Therapeutics Inc new | 1 | 0.00 % |
Market cap and industry share for the rest of Protagenic Therapeutics Inc New's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Protagenic Therapeutics Inc New's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 456 | Avenue Therapeutics Inc | 1 | - |
| 457 | Hcw Biologics Inc | 1 | -68.69 % |
| 458 | Jupiter Neurosciences Inc | 1 | 61.76 % |
| 459 | International Stem Cell Corporation | 1 | - |
| 460 | Genprex Inc | 1,234 | 12.3% |
| 461 | Protagenic Therapeutics Inc new | 1 | -74.77 % |
| 462 | Axim Biotechnologies Inc | 1,234 | 12.3% |
| 463 | Evofem Biosciences Inc | 1,234 | 12.3% |
| 464 | Skinvisible Inc | 1,234 | 12.3% |
| 465 | Pmgc Holdings Inc | 1,234 | 12.3% |
| 466 | The Greater Cannabis Company Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Protagenic Therapeutics Inc New's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Protagenic Therapeutics Inc New's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 0.3x | 26.6x | -26.4x |
| EV / EBITDA | 0.2x | 15.9x | -15.7x |
| P/B | -1.5x | 4.3x | -5.8x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -9.82 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Protagenic Therapeutics Inc New's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | -282.74 % | - | 386.76 % | -27.01 % | -22.42 % | -46.08 % | - | - |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Protagenic Therapeutics Inc New's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Protagenic Therapeutics Inc New falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Protagenic Therapeutics Inc New's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Protagenic Therapeutics Inc New's dedicated Suppliers and Customers pages, not here.
Protagenic Therapeutics Inc New's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Protagenic Therapeutics Inc New falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Protagenic Therapeutics Inc New's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (46.80 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Protagenic Therapeutics Inc New's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Protagenic Therapeutics Inc new | 0.35 | 0.40 | - |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
Sign in to see all peers for Protagenic Therapeutics Inc new.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Protagenic Therapeutics Inc New's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Protagenic Therapeutics Inc new | Q2 2026 | - | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| PEERS TOTAL | +11.9 % | -5.3 % |
Sign in to see all peers for Protagenic Therapeutics Inc new.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Protagenic Therapeutics Inc New's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Protagenic Therapeutics Inc new | Q2 2026 | - | - |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
Sign in to see all peers for Protagenic Therapeutics Inc new.
Protagenic Therapeutics Inc New's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Protagenic Therapeutics Inc new | 137.58% | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
Sign in to see all peers for Protagenic Therapeutics Inc new.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Protagenic Therapeutics Inc New's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Protagenic Therapeutics Inc new | 0.23 | - |
| Eli Lilly And Company | 43.96 | 13.99 |
| Johnson and Johnson | 41.79 | 6.81 |
| Abbvie Inc | 50.14 | 7.82 |
| Merck and Co Inc | 118.32 | 5.44 |
| Novartis Ag | 22.73 | 5.61 |
| PEERS AVERAGE | 39.45 | 6.35 |
Sign in to see all peers for Protagenic Therapeutics Inc new.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.